Search

Your search keyword '"Dotan, I."' showing total 761 results
Start Over Author "Dotan, I."
761 results on '"Dotan, I."'

2. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus

Author

Abreu, M, Ahuja, V, Allez, M, Ananthakrishnan, A, Bemelman, W, Bernstein, C, Braun, J, Chowers, Y, Colombel, J-F, Danese, S, D'Haens, G, D'Hoore, A, Dignass, A, Dotan, I, Dubinsky, M, Ekbom, A, Fleshner, P, Gasche, C, Gassull, MA, Gearry, R, Ghosh, S, Gibson, P, Griffiths, A, Halfvarson, J, Hanauer, S, Harpaz, N, Hart, A, Hibi, T, Kamm, M, Kaplan, G, Kaser, A, Korelitz, B, Kotze, P, Koutroubakis, I, Kruis, W, Lakatos, P, Lewis, J, Lindsay, J, Loftus, E, Louis, E, Lukas, M, Magro, F, Mahadevan, U, Mantzaris, G, Mary, J-Y, McGovern, D, Moum, B, Munkholm, P, Neurath, M, Ng, S, O'Morain, C, Oresland, T, Panaccione, R, Panes, J, Panis, Y, Pemberton, J, Peyrin-Biroulet, L, Prantera, C, Rachmilewitz, D, Ran, Z, Reinisch, W, Remzi, F, Rhodes, J, Riddell, R, Rogler, G, Rubin, D, Sachar, D, Sandborn, W, Sands, B, Sartor, B, Schoelmerich, J, Schreiber, S, Siegel, C, Siegmund, B, Silverberg, M, Söderholm, J, Sood, A, Spinelli, A, Stange, E, Steinwurz, F, Targan, S, Travis, S, Turner, D, Tysk, C, Vatn, M, Vermeire, S, Watanabe, M, Yamamoto, T, Yamamoto-Furusho, J, Ananthakrishnan, Ashwin N, Kaplan, Gilaad G, Bernstein, Charles N, Burke, Kristin E, Lochhead, Paul J, Sasson, Alexa N, Agrawal, Manasi, Tiong, Jimmy Ho Tuan, Steinberg, Joshua, Kruis, Wolfgang, Steinwurz, Flavio, Ahuja, Vineet, Ng, Siew C, Rubin, David T, Colombel, Jean-Frederic, and Gearry, Richard

Published
2022
Full Text
View/download PDF

3. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1

Author

Loftus EV Jr, Sands BE, Colombel JF, Dotan I, Khalid JM, Tudor D, and Geransar P

Subjects
vedolizumab, ulcerative colitis, corticosteroid, anti-tumor necrosis factor alpha, clinical remission, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Edward V Loftus Jr,1 Bruce E Sands,2 Jean-Frédéric Colombel,2 Iris Dotan,3 Javaria Mona Khalid,4 David Tudor,5 Parnia Geransar5 1Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA; 2The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA; 3Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 4Takeda International – UK Branch, London, UK; 5Takeda Pharmaceuticals International AG, Zurich, SwitzerlandCorrespondence: Edward V Loftus JrDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USATel +1-507-284-2511Email loftus.edward@mayo.eduBackground: Corticosteroid-free clinical remission is important in ulcerative colitis.Objective: This GEMINI 1 post hoc analysis evaluated vedolizumab efficacy in achieving sustained corticosteroid-free clinical remission in moderately to severely active ulcerative colitis.Materials and Methods: GEMINI 1 included a 6-week induction period followed by a 46-week maintenance period. Patients received stable corticosteroid dosing at baseline/during induction and tapered dosing during maintenance. Analysis groups included vedolizumab (induction and maintenance); vedolizumab/placebo (vedolizumab induction, placebo maintenance); and placebo (induction and maintenance). The primary endpoint was sustained corticosteroid-free clinical remission (partial Mayo score ≤ 2, no individual subscore > 1, for ≥ 32 weeks). Multivariate analyses identified covariates associated with the primary endpoint. Safety endpoints included adverse events.Results: Baseline demographics and concomitant corticosteroid use were similar across groups (n=454). A greater proportion (95% confidence interval) of the vedolizumab group achieved sustained corticosteroid-free clinical remission (10.2% [6.9 to 13.6]) vs the placebo group (1.4% [0.0 to 7.3]; difference 8.9% [– 3.8 to 21.4]). Proportions were similar between the vedolizumab/placebo and placebo groups. Covariates associated with sustained corticosteroid-free clinical remission (odds ratio [95% confidence interval]) were treatment (vedolizumab vs placebo: 9.35 [1.25 to 71.43]; p=0.0605), anti-tumor necrosis factor alpha exposure (yes vs no: 0.26 [0.12 to 0.57]; p=0.0008), and disease duration (≤ 2 vs > 2 years: 2.66 [0.99– 7.19]; p=0.0531). Adverse events were similar across groups.Conclusion: A numerically greater proportion of vedolizumab-treated patients with ulcerative colitis achieved sustained corticosteroid-free clinical remission. Vedolizumab treatment, no previous anti-tumor necrosis factor alpha exposure, and shorter disease duration were associated with sustained corticosteroid-free clinical remission.Clinicaltrials.gov: NCT00783718.Keywords: vedolizumab, ulcerative colitis, corticosteroid, anti-tumor necrosis factor alpha, clinical remission

Published
2020

5. The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease

Author

Lopetuso, L, Deleu, S, Godny, L, Petito, V, Puca, P, Facciotti, F, Sokol, H, Ianiro, G, Masucci, L, Abreu, M, Dotan, I, Costello, S, Hart, A, Iqbal, T, Paramsothy, S, Sanguinetti, M, Danese, S, Tilg, H, Cominelli, F, Pizarro, T, Armuzzi, A, Cammarota, G, Gasbarrini, A, Vermeire, S, Scaldaferri, F, Lopetuso L. R., Deleu S., Godny L., Petito V., Puca P., Facciotti F., Sokol H., Ianiro G., Masucci L., Abreu M., Dotan I., Costello S. P., Hart A., Iqbal T. H., Paramsothy S., Sanguinetti M., Danese S., Tilg H., Cominelli F., Pizarro T. T., Armuzzi A., Cammarota G., Gasbarrini A., Vermeire S., Scaldaferri F., Lopetuso, L, Deleu, S, Godny, L, Petito, V, Puca, P, Facciotti, F, Sokol, H, Ianiro, G, Masucci, L, Abreu, M, Dotan, I, Costello, S, Hart, A, Iqbal, T, Paramsothy, S, Sanguinetti, M, Danese, S, Tilg, H, Cominelli, F, Pizarro, T, Armuzzi, A, Cammarota, G, Gasbarrini, A, Vermeire, S, Scaldaferri, F, Lopetuso L. R., Deleu S., Godny L., Petito V., Puca P., Facciotti F., Sokol H., Ianiro G., Masucci L., Abreu M., Dotan I., Costello S. P., Hart A., Iqbal T. H., Paramsothy S., Sanguinetti M., Danese S., Tilg H., Cominelli F., Pizarro T. T., Armuzzi A., Cammarota G., Gasbarrini A., Vermeire S., and Scaldaferri F.

Abstract

Background Several randomised clinical trials (RCTs) performing faecal microbiota transplantation (FMT) for the management of inflammatory bowel disease (IBD), particularly for ulcerative colitis, have recently been published, but with major variations in study design. These include differences in administered dose, route and frequency of delivery, type of placebo and evaluated endpoints. Although the overall outcomes appear to be promising, they are highly dependent on both donor and recipient factors. Objective To develop concensus-based statements and recommendations for the evaluation, management and potential treatment of IBD using FMT in order to move towards standardised practices. Design An international panel of experts convened several times to generate evidence-based guidelines by performing a deep evaluation of currently available and/or published data. Twenty-five experts in IBD, immunology and microbiology collaborated in different working groups to provide statements on the following key issues related to FMT in IBD: (A) pathogenesis and rationale, (B) donor selection and biobanking, (C) FMT practices and (D) consideration of future studies and perspectives. Statements were evaluated and voted on by all members using an electronic Delphi process, culminating in a plenary consensus conference and generation of proposed guidelines. Results and conclusions Our group has provided specific statements and recommendations, based on best available evidence, with the end goal of providing guidance and general criteria required to promote FMT as a recognised strategy for the treatment of IBD.

Published
2023

6. P1206 Mechanistic implications of the Mediterranean diet in patients with newly diagnosed Crohn’s disease- multi-omic analysis of a prospective cohort

Author

Godny, L, primary, Elial-Fatal, S, additional, Arrouasse, J, additional, Sharar Fischler, T, additional, Reshef, L, additional, Kutokov, Y, additional, Cohen, S, additional, Pfeffer-Gik, T, additional, Barkan, R, additional, Shakhman, S, additional, Friedenberg, A, additional, Pauker, M H, additional, Rabinowitz, K, additional, Shaham Barda, E, additional, Eran-Banai, H, additional, Ollech, J, additional, Snir, Y, additional, Broitman, Y, additional, Avni-Biron, I, additional, Gophna, U, additional, Yanai, H, additional, and Dotan, I, additional

Published
2024
Full Text
View/download PDF

9. P1207 Microbiome composition determines sustained remission after the Crohn’s Disease Exclusion Diet (CDED) with or without Partial Enteral Nutrition in adults with mild-moderate Crohn’s disease; Results from the CDED-AD Pilot Randomized Controlled Trial

Author

Sigall-Boneh, R, primary, Organ, S, additional, Yanai, H, additional, Maharshak, N, additional, Dotan, I, additional, Abramas, L, additional, Wine, E, additional, Widesma, N, additional, Gu, H, additional, Bielawski, J, additional, Dunn, K, additional, and Van Limbergen, J, additional

Published
2024
Full Text
View/download PDF

13. P321 Development and validation of an Integrated Risk Score for future risk of Crohn’s disease in healthy first-degree relatives: The CCC-GEM Project, a multicentre prospective cohort study

Author

Lee Dr., S H, primary, Turpin, W, additional, Espin-Garcia, O, additional, Leibovitzh, H, additional, Xue, M, additional, Raygoza-Garay, J A, additional, Grana, L, additional, Smith, M I, additional, Goethel, A, additional, Madsen L., K, additional, Avni-Biron, I, additional, Dotan, I, additional, Shomron, B H, additional, Griffiths, A M, additional, Steinhart, A H, additional, Silverberg, M S, additional, Turner, D, additional, Bernstein, C N, additional, Feagan, B G, additional, Moayeddi, P, additional, Paterson, A, additional, Guttman, D, additional, Xu, W, additional, and Croitoru, K, additional

Published
2024
Full Text
View/download PDF

14. DOP29 Capsule endoscopy-guided proactive treatment versus standard treatment of patients with quiescent Crohn’s Disease: The CURE-CD randomized controlled trial

Author

Ben-Horin, S, primary, Lahat, A, additional, Ungar, B, additional, Ukashi, O, additional, Yablecovitch, D, additional, Amitai, M M, additional, Haberman, Y, additional, Selinger, L, additional, Talan-Asher, A, additional, Kriger-Sharabi, O, additional, Naftali, T, additional, Ron, Y, additional, Yanai, H, additional, Dotan, I, additional, Kopylov, U, additional, and Eliakim, R, additional

Published
2024
Full Text
View/download PDF

16. Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study

Author

Friedman MY, Leventer-Roberts M, Rosenblum J, Zigman N, Goren I, Mourad V, Lederman N, Cohen N, Matz E, Dushnitzky DZ, Borovsky N, Hoshen MB, Focht G, Avitzour M, Shachar Y, Chowers Y, Eliakim R, Ben-Horin S, Odes S, Schwartz D, Dotan I, Israeli E, Levi Z, Benchimol EI, Balicer RD, and Turner D

Subjects
Inflammatory Bowel Diseases, Crohn's disease, Ulcerative colitis, search algorithms, validation, case ascertainment, Israel, administrative database research., Infectious and parasitic diseases, RC109-216
Abstract

Mira Y Friedman,1,2 Maya Leventer-Roberts,3 Joseph Rosenblum,4 Nir Zigman,4 Iris Goren,4 Vered Mourad,4 Natan Lederman,5 Nurit Cohen,5 Eran Matz,6 Doron Z Dushnitzky,6 Nirit Borovsky,6 Moshe B Hoshen,3 Gili Focht,1 Malka Avitzour,1 Yael Shachar,1 Yehuda Chowers,7 Rami Eliakim,8 Shomron Ben-Horin,8 Shmuel Odes,9 Doron Schwartz,9 Iris Dotan,10 Eran Israeli,11 Zohar Levi,10 Eric I Benchimol,12–14 Ran D Balicer,3 Dan Turner1 On behalf of the Israeli IBD Research Nucleus (IIRN) 1The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel; 2Braun School of Public and Community Medicine, The Hebrew University – Hadassah Medical Center, Jerusalem, Israel; 3Clalit Research Institute, Chief’s Office, Clalit Health Services, Tel Aviv, Israel; 4Maccabi Healthcare Services, Tel Aviv, Israel; 5Meuhedet Health Services, Tel Aviv, Israel; 6Leumit Health Services, Tel Aviv, Israel; 7Department of Gastroenterology, Rambam Health Care Campus, Bruce Rappaport School of Medicine, Technion Israel Institute of Technology, Haifa, Israel; 8Department of Gastroenterology, Chaim Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; 9Department of Gastroenterology and Hepatology, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel; 10Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; 11Institute of Gastroenterology and Liver Diseases, Hadassah Medical Center, Hebrew University, Jerusalem, Israel; 12CHEO Inflammatory Bowel Disease Centre, Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada; 13Department of Pediatrics and School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, ON, Canada; 14Institute for Clinical Evaluative Sciences, Ottawa, ON, Canada Background: Before embarking on administrative research, validated case ascertainment algorithms must be developed. We aimed at developing algorithms for identifying inflammatory bowel disease (IBD) patients, date of disease onset, and IBD type (Crohn’s disease [CD] vs ulcerative colitis [UC]) in the databases of the four Israeli Health Maintenance Organizations (HMOs) covering 98% of the population. Methods: Algorithms were developed on 5,131 IBD patients and 2,072 controls, following independent chart review (60% CD and 39% UC). We reviewed 942 different combinations of clinical parameters aided by mathematical modeling. The algorithms were validated on an independent cohort of 160,000 random subjects. Results: The combination of the following variables achieved the highest diagnostic accuracy: IBD-related codes, alone if more than five to six codes or combined with purchases of IBD-related medications (at least three purchases or ≥3 months from the first to last purchase) (sensitivity 89%, specificity 99%, positive predictive value [PPV] 92%, negative predictive value [NPV] 99%). A look-back period of 2–5 years (depending on the HMO) without IBD-related codes or medications best determined the date of diagnosis (sensitivity 83%, specificity 68%, PPV 82%, NPV 70%). IBD type was determined by the majority of CD/UC codes of the three recent contacts or the most recent when less than three contacts were recorded (sensitivity 92%, specificity 97%, PPV 97%, NPV 92%). Applying these algorithms, a total of 38,291 IBD patients were residing in Israel, corresponding to a prevalence rate of 459/100,000 (0.46%). Conclusion: The application of the validated algorithms to Israel’s administrative databases will now create a large and accurate ongoing population-based cohort of IBD patients for future administrative studies. Keywords: inflammatory bowel diseases, Crohn’s disease, ulcerative colitis, search algorithms, validation, case ascertainment, Israel, administrative database research

Published
2018

17. Ein globaler Consensus zu Definitionen, Diagnostik und Behandlungsmanagement des fibrostenotischen Morbus Crohn des terminalen Ileums

Author

Bettenworth, D., additional, Baker, M. E., additional, Fletcher, J. G., additional, Jairath, V., additional, Lu, C., additional, Bemelman, W., additional, d’Haens, G., additional, d’Hoore, A., additional, Dignass, A., additional, Dotan, I., additional, Feakins, R., additional, Fleshner, P., additional, Ha, C., additional, Henderson, G., additional, Lyu, R., additional, Panes, J., additional, Rogler, G., additional, Mao, R., additional, Rimola, J., additional, Sandborn, W. J., additional, Ng, S. C., additional, Siegmund, B., additional, Silverberg, M., additional, Taylor, S. A., additional, Verstockt, B., additional, Gordon, I. O., additional, Bruining, D. H., additional, Feagan, B. G., additional, and Rieder, F., additional

Published
2023
Full Text
View/download PDF

19. Magnetic resonance enterography or video capsule endoscopy – what do Crohn’s disease patients prefer?

Author

Lahat A, Kopylov U, Amitai MM, Neuman S, Levhar N, Yablecovitch D, Avidan B, Yanai H, Dotan I, Chowers Y, Weiss B, Ben-Horin S, and Eliakim R

Subjects
Inflammatory Bowel Disease, Crohn's, imaging, MRE, capsule endoscopy, patients preference, Medicine (General), R5-920
Abstract

Adi Lahat,1,2 Uri Kopylov,1,2 Marianne M Amitai,3 Sandra Neuman,1,2 Nina Levhar,1,2 Doron Yablecovitch,1,2 Benjamin Avidan,1,2 Henit Yanai,2,4 Iris Dotan,2,4 Yehuda Chowers,5,6 Batya Weiss,7 Shomron Ben-Horin,1,2,* Rami Eliakim1,2,* On behalf of the Israeli IBD Research Network (IIRN) 1Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Department of Diagnostic Imaging, Chaim Sheba Medical Center, Tel Hashomer, Israel; 4IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Tel Aviv, Isarel; 5Rambam Health Care Campus, Haifa, Israel; 6Bruce Rappaport School of Medicine, Technion Israel Institute of Technology, Haifa, Israel; 7Edmond and Lily Safra Children’s Hospital, Tel Hashomer, Israel *These authors contributed equally to this work Background: Despite differences in the information obtained by capsule endoscopy (CE) and magnetic resonance enterography (MRE), one of these modalities is usually needed when evaluating disease activity. There are no data on patients’ preference that would help guide the choice between these two modalities in these instances.Aim: To compare patients’ tolerance and preference to MRE versus CE.Patients and methods: Patients with known small bowel Crohn’s disease (CD) in clinical remission (Crohn’s disease activity index [CDAI]

Published
2016

20. P664 Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD

Author

Vieujean, S, primary, Lindsay, J O, additional, Rubin, D, additional, D’Amico, F, additional, Ahuja, V, additional, Silverberg, M S, additional, Sood, A, additional, Yamamoto-Furusho, J K, additional, Nagahori, M, additional, Watanabe, M, additional, Koutroubakis, I E, additional, Foteinogiannopoulou, K, additional, Walsh, A, additional, Outtier, A, additional, Abreu, M T, additional, Dubinsky, M, additional, Siegel, C, additional, Louis, E, additional, Dotan, I, additional, Reinisch, W, additional, Danese, S, additional, and Peyrin-Biroulet, L, additional

Published
2023
Full Text
View/download PDF

25. P560 Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trial

Author

Ben-Horin, S, primary, Salomon, N, additional, Karampekos, G, additional, Viazis, N, additional, Lahat, A, additional, Ungar, B, additional, Eliakim, R, additional, Kriger-Sharabi, O, additional, Reiss-Mintz, H, additional, Yanai, H, additional, Dotan, I, additional, Zittan, E, additional, Maharshak, N, additional, Hirsch, A, additional, Weitman, M, additional, Mantzaris, G J, additional, and Kopylov, U, additional

Published
2023
Full Text
View/download PDF

26. P458 Low adherence to Mediterranean diet is associated with increased adipose tissue in patients with ulcerative colitis (UC) after pouch surgery: a cross sectional study

Author

Pfeffer-Gik, T, primary, Godny, L, additional, Ollech, J, additional, Wasserberg, N, additional, White, I, additional, Cohen, S, additional, Broitman, Y, additional, Avni-Biron, I, additional, Banai, H, additional, Snir, Y, additional, Yanai, H, additional, Yackobovich Gavan, M, additional, Shimon, I, additional, Tsvetov, G, additional, Barkan, R, additional, and Dotan, I, additional

Published
2023
Full Text
View/download PDF

27. P292 Complications in elderly-onset Inflammatory Bowel Diseases – A population-based study from the epidemiological database of the Israeli IBD Research Nucleus (Epi-IIRN)

Author

Ben Hur, D, primary, Lebedenko, B, additional, Issaschar, G, additional, Moshe, R, additional, Lujan, R, additional, Focht, G, additional, Loewenberg Weisband, Y, additional, Kariv, R, additional, Ledderman, N, additional, Matz, E, additional, Dotan, I, additional, Turner, D, additional, Pinto, G, additional, and Waterman, M, additional

Published
2023
Full Text
View/download PDF

33. P270 A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease

Author

Bettenworth, D, primary, Baker, M E, additional, Bemelmann, W, additional, Bruining, D, additional, D’Haens, G, additional, D’Hoore, A, additional, Dignass, A, additional, Dotan, I, additional, Feagan, B G, additional, Feakins, R, additional, Fleshner, P, additional, Fletcher, J G, additional, Gordon, I, additional, Ha, C, additional, Gaylyn, H, additional, Jairath, V, additional, Lu, C, additional, Lyu, R, additional, Ng, S C, additional, Panes, J, additional, Rogler, G, additional, Mao, R, additional, Rimola, J, additional, Sandborn, W J, additional, Siegmund, B, additional, Silverberg, M S, additional, Taylor, S, additional, Verstockt, B, additional, and Rieder, F, additional

Published
2023
Full Text
View/download PDF

34. P575 Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

Author

Siegmund, B, primary, Komori, H K, additional, Abreu, M T, additional, Vermeire, S, additional, Dotan, I, additional, Goetsch, M, additional, Crosby, C, additional, Ryan, R, additional, Woolcott, J, additional, and Danese, S, additional

Published
2023
Full Text
View/download PDF

37. P568 Patients with ulcerative colitis after pouch surgery are at risk for low spinal bone mineral density: a cross sectional study

Author

Pfeffer-Gik, T, primary, Godny, L, additional, Ollech, J, additional, Wasserberg, N, additional, White, I, additional, Barkan, R, additional, Cohen, S, additional, Avni-Biron, I, additional, Banai, H, additional, Snir, Y, additional, Yanai, H, additional, Yackobovich Gavan, M, additional, Shimon, I, additional, Tsvetov, G, additional, Broitman, Y, additional, and Dotan, I, additional

Published
2023
Full Text
View/download PDF

42. DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation study

Author

Kopylov, U, Verstockt, B, Biedermann, L, Sebastian, S, Pugliese, D, Sonnenberg, E, Steinhagen, P R, Arebi, N, Ron, Y, Kucharzik, T, Roblin, X, Ungar, B, Bar-Gil Shitrit, A, Ardizzone, S, Molander, P, Coletta, M, Peyrin-Biroulet, L, Bossuyt, P, Avni-Biron, I, Tsoukal, E I, Allocca, M, Katsanos, K, Raine, T, Sipponen, T, Fiorino, G, Ben-Horin, S, Eliakim, R, Armuzzi, A, Siegmund, B, Baumgart, D C, Kamperidis, N, Maharshak, N, Maaser, C, Mantzaris, G, Yanai, H, Christodoulou, D, Dotan, I, and Ferrante, M

Published
2018
Full Text
View/download PDF

43. Comparison of insulin dose adjustments made by artificial intelligence based decision support system and by physicians in people with type 1 diabetes using multiple daily injections therapy

Author

Nimri R, Tirosh A, Muller I, Shtrit Y, Kraljević I, Alonso MM, Milicic T, Saboo B, Deeb A, Christoforidis A, M den Brinker, Bozzetto L, Bolla AM, Krcma M, Rabini RA, Tabba S, Vazeou-Gerasimidi A, Maltoni G, Giani E, Dotan I, Liberty IF, Toledano Y, Kordonouri O, Bratina N, Dovc K, Biester T, Atlas E, and Phillip M

Subjects
General Economics, Econometrics and Finance
Published
2022
Full Text
View/download PDF

45. Increasing adherence to the Mediterranean diet and lifestyle is associated with reduced fecal calprotectin and intra-individual changes in microbial composition of healthy subjects

Author

Godny, L., primary, Reshef, L., additional, Sharar Fischler, T., additional, Elial-Fatal, S., additional, Pfeffer-Gik, T., additional, Raykhel, B., additional, Rabinowitz, K., additional, Levi-Barda, A., additional, Perets, TT., additional, Barkan, R., additional, Goren, I., additional, Ollech, JE., additional, Yanai, H., additional, Gophna, U., additional, and Dotan, I., additional

Published
2022
Full Text
View/download PDF

49. P721 A switch in the prevalence ratio of Crohnʼs disease vs. ulcerative colitis in Israel between 2003 and 2015 – a report from the epi-IIRN group

Author

Friedman, M., Odes, S., Balicer, R., Hoshen, M., Cohen, D., Rosenblum, J., Zigman, N., Goren, I., Lederman, N., Matz, E., Dushnitzky, D., Borovsky, N., Gavish, M., Focht, G., Avitzour, M., Axelrod, R., Chowers, Y., Eliakim, R., Ben-Horin, S., Dotan, I., Israeli, E., Levy, Z., Benchimol, E., and Turner, D.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results